Bicara Therapeutics Inc. (BCAX) vs Climb Bio Inc (CLYM)
Bicara Therapeutics Inc. and Climb Bio Inc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BCAX vs CLYM, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Bicara Therapeutics Inc. (BCAX) | Climb Bio Inc (CLYM) | |
|---|---|---|
| Market cap | $1.4B | $0.6B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-137.95M | $-59.85M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -34.4% | -37.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Performance — BCAX vs CLYM
Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.
| Bicara Therapeutics Inc. (BCAX) | Climb Bio Inc (CLYM) | |
|---|---|---|
| 1-year return | 125.2% | 765.3% |
| 3-year return | — | 283.2% |
| 5-year return | — | — |
| 10-year return | — | — |
| 52-week range | $8.48–$24.25 | $1.16–$12.48 |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BCAX vs CLYM breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BCAX's full financials → Open CLYM's full financials →More comparisons
Frequently asked questions
Which is bigger, BCAX or CLYM?
Bicara Therapeutics Inc. is larger by market capitalization — $1.4B versus $0.6B.
Which grows faster, BCAX or CLYM?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.